CNBX - Cannabics Pharmaceuticals Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.4200
+0.0050 (+1.20%)
At close: 3:57PM EST
Stock chart is not supported by your current browser
Previous Close0.4150
Open0.0000
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume191,277
Market Cap55.416M
Beta (3Y Monthly)-4.39
PE Ratio (TTM)N/A
EPS (TTM)-0.03
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Cannabics Pharmaceuticals to Co-Sponsor the Canada Cannabis House at the World Economic Forum in Davos
    PR Newswire22 hours ago

    Cannabics Pharmaceuticals to Co-Sponsor the Canada Cannabis House at the World Economic Forum in Davos

    TEL AVIV, Israel and BETHESDA, Maryland, Jan. 22, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced that Mr. Eyal Barad, Co-Founder and CEO, and Dr. Eyal Ballan, Co-Founder and CTO, will be in Davos, Switzerland in January, 2019.

  • Cannabics Pharmaceuticals Converts $1 Million Loan Into Common Shares of Seedo
    PR Newswire15 days ago

    Cannabics Pharmaceuticals Converts $1 Million Loan Into Common Shares of Seedo

    TEL AVIV, Israel, Jan. 8, 2019 /PRNewswire/ -- Seedo Corp. (SEDO), a high-tech company providing the world's first fully automated and controlled indoor growing machine for the organic cannabis and agriculture markets, today announced that U.S.-based partner and investor Cannabics Pharmaceuticals Inc., a leader in personalized cannabinoid medicine focused on cancer and its side effects, is converting its $1 million convertible loan to Seedo into common shares of the company.

  • Cannabics Pharmaceuticals to be present during the J.P. Morgan Healthcare Conference In San Francisco
    PR Newswire23 days ago

    Cannabics Pharmaceuticals to be present during the J.P. Morgan Healthcare Conference In San Francisco

    TEL AVIV, Israel and BETHESDA, Md., Dec. 31, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced that Mr. Eyal Barad, CEO, will be in San Francisco in January 2019 during the J.P. Morgan Healthcare Conference. The company will be meeting with Investors as well as potential partners such as Pharmaceuticals and Biotech firms from Monday, January 7th to Wednesday, January 9th. Mr. Barad will provide an overview on the company's mission and provide insight into the path forward towards bringing a highly valuable and needed solution to cancer patients.

  • Cannabics Pharmaceuticals Announces New Provisional Patent Application for Personalized Cannabimetic Compositions Modeling and Production
    PR Newswire28 days ago

    Cannabics Pharmaceuticals Announces New Provisional Patent Application for Personalized Cannabimetic Compositions Modeling and Production

    TEL AVIV, Israel and BETHESDA, Maryland, Dec. 26, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has filed a provisional patent application with the US Patent office. The patent covers the Company's technology that will enable the transfer of data from its proprietary personalization platform of cannabis strains and cancer to medical cannabis businesses worldwide and overcome the limitations of exporting and importing cannabinoid compounds due to regulation.

  • Market Exclusivelast month

    Cannabis Stock News Daily Roundup December 12

    Cannabis News New York-based medical cannabis firm Columbia Care has received approval and license from the State of Virginia to produce cannabis oil. The company, recently valued at $1.35 billion, is planning to open its dispensary in Portsmouth, Virginia, in the spring of 2019. They plan to cultivate, produce and dispense cannabidiol (CBD) and tetrahydrocannabinolic […] The post Cannabis Stock News Daily Roundup December 12 appeared first on Market Exclusive.

  • Cannabics Pharmaceuticals Prepares ISO Application for Its Diagnostics Platform Towards Commercialization
    PR Newswirelast month

    Cannabics Pharmaceuticals Prepares ISO Application for Its Diagnostics Platform Towards Commercialization

    TEL AVIV, Israel and BETHESDA, Maryland, Dec. 11, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has started the accreditation process in accordance with ISO 15189:2012 for its drug screening and diagnostics laboratory, which it expects to receive by the end of next year. ISO is the accepted "International Organization for Standardization", and ISO 15189:2012 is the international standard for quality management and competence for Medical Laboratories by regulators and accrediting bodies.

  • Market Exclusive2 months ago

    Cannabis Stock News Daily Roundup November 29

    The global legal cannabis market is projected to hit $146.4 billion by end of 2025, according to research by Grand View Research. The legal cannabis industry is gaining traction worldwide due to high demand among consumers for recreational and medical products. Recreational cannabis spending is projected to hit $35 Billion mark, while medical cannabis spending […] The post Cannabis Stock News Daily Roundup November 29 appeared first on Market Exclusive.

  • PR Newswire2 months ago

    /C O R R E C T I O N -- Cannabics Pharmaceuticals Inc./

    In the news release, Cannabics Pharmaceuticals Announces New Provisional Patent Application for Magnetic Targeting of Cannabinoids, issued Nov. 28, 2018 by Cannabics Pharmaceuticals Inc. over PR Newswire, ...

  • CEO of Cannabics Pharmaceuticals Presenting at 11th Annual LD Micro Conference, on December 5th, 2018 in LA, California
    PR Newswire2 months ago

    CEO of Cannabics Pharmaceuticals Presenting at 11th Annual LD Micro Conference, on December 5th, 2018 in LA, California

    TEL AVIV, Israel and BETHESDA, Maryland, Nov. 27, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that Mr. Eyal Barad, CEO, will be presenting at the LD Micro Main Event. The presentation will provide an overview of the company's mission and activities and provide insight into the path forward towards bringing a valuable and needed service to cancer patients, who are using cannabis. Mr. Barad will also describe how the company plans on leveraging its technology to solidify partnerships which create long term value.

  • GlobeNewswire3 months ago

    Cannabics Pharmaceuticals Inc. CEO talks with Uptick Newswire’s Stock Day Podcast About Cancer Research in the Cannabinoid Sector

    Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) (the “Company”) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient's profile. “Cannabics Pharmaceuticals started about 5 years ago and today is mostly focused on the palliative and anti-tumor effects cannabinoids with cancer,” explained Barad.

  • PR Newswire3 months ago

    CEO of Cannabics Pharmaceutical Speaking at MJBizCon 2018 in Las Vegas

    TEL AVIV, Israel and BETHESDA, Maryland, Nov. 1, 2018 /PRNewswire/ --  Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced their CEO, Eyal Barad, will speak on a panel at the Marijuana Business Conference (MJBizCon) held in Las Vegas. MJBizCon 2018 is the flagship event of MJBizDaily and one of the preeminent conferences helping to drive business deals and forge valuable connections with cannabis professionals in the sector. At the conference, Mr. Barad will join thought leaders in the space on November 13th during "The Business of Hemp Forum" from 2:30 p.m. - 3:00 p.m. PT.

  • Cannabics Pharmaceuticals Granted Patent in South Africa for Its Personalized Cannabinoid Based Diagnostics
    PR Newswire3 months ago

    Cannabics Pharmaceuticals Granted Patent in South Africa for Its Personalized Cannabinoid Based Diagnostics

    TEL AVIV, Israel and BETHESDA, Maryland, Oct. 25, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has been granted its patent for its core technology by the South Africa Patent Office. Following the patent's approval in Israel in September 2018, this patent encompasses the systems and methods required to produce data on the interaction between different cannabinoids and cancer cells. This technology enables screening the effects of a multitude of compounds derived from the cannabis plant on cancer cell lines and biopsies.

  • Cannabics Pharmaceuticals Announces Attendance at the CannMed 2018 Conference, Held at the UCLA Luskin Conference Center, Los Angeles, October 22-24
    PR Newswire3 months ago

    Cannabics Pharmaceuticals Announces Attendance at the CannMed 2018 Conference, Held at the UCLA Luskin Conference Center, Los Angeles, October 22-24

    TEL AVIV, Israel and BETHESDA, Maryland, Oct. 19, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that Mr. Eyal Barad, Cannabics Pharmaceuticals' Co-Founder and CEO, will be in attendance at the 2018 CannMed conference, held at the UCLA Luskin Conference Center, Los Angeles, between October 22nd – 24th , 2018. CannMed 2018, a Personalized Cannabinoid Medicine Conference, attracts medical cannabis researchers from multiple countries who present their latest findings with regards to the efficacy of treating a variety of conditions with cannabis.

  • PR Newswire3 months ago

    Cannabics Pharmaceuticals Announces Positive Results for Pilot Study on Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

    Preliminary findings showed more than 80 percent of patients had increase in appetite and 60 percent of patients had over 10 percent weight increase TEL AVIV , Israel and BETHESDA, Maryland, Oct. 16, 2018 ...

  • Join Cannabics Pharmaceuticals at the 3rd CannX Medical Cannabis Conference, Held at Tel-Aviv Convention Center, Israel, October 14-16, 2018
    PR Newswire3 months ago

    Join Cannabics Pharmaceuticals at the 3rd CannX Medical Cannabis Conference, Held at Tel-Aviv Convention Center, Israel, October 14-16, 2018

    TEL AVIV, Israel and BETHESDA, Maryland, Oct. 9, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that members of its management team will be attending the 3rd CannX Medical Cannabis Conference, to be held in the Tel Aviv Convention Centre, on October 14th – 16th  2018, and will be available for one-on-one meetings. The 3rd International Medical Cannabis Conference, CannX, is an annual event for global leaders in areas of Medical Cannabis to convene, explore and present the latest scientific and clinical research in the field. At the convention, Dr. Gil Bar-Sela is scheduled to present his findings of the clinical trial Cannabics completed.

  • PR Newswire4 months ago

    Cannabics Pharmaceuticals Inc. Prices $7,500,000 Registered Direct Offering

    CANNABICS PHARMACEUTICALS INC. (CNBX) ("Cannabics" or the "Company"), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced it has entered into definitive agreements with investors for the purchase and sale of (i) 10,000,000 shares of common stock, par value $0.0001 per share, and (ii) warrants to purchase up to 5,000,000 shares of common stock at a combined offering price of $0.75 per share and warrant, pursuant to a registered direct offering. The warrants will have an exercise price of $1.00 per share, will be immediately exercisable and will expire five years from the date of issuance. The warrants contain customary anti-dilution adjustment provisions and an exercise price protection provision for subsequent issuances below the then current exercise price.

  • Cannabics Pharmaceuticals Inc. Prices $7,500,000 Registered Direct Offering
    PR Newswire4 months ago

    Cannabics Pharmaceuticals Inc. Prices $7,500,000 Registered Direct Offering

    TEL AVIV, Israel and BETHESDA, Maryland, Sept. 24, 2018 /PRNewswire/ -- CANNABICS PHARMACEUTICALS INC. (CNBX) ("Cannabics" or the "Company"), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced it has entered into definitive agreements with investors for the purchase and sale of (i) 10,000,000 shares of common stock, par value $0.0001 per share, and (ii) warrants to purchase up to 5,000,000 shares of common stock at a combined offering price of $0.75 per share and warrant, pursuant to a registered direct offering. The gross proceeds of the offering will be approximately $7,500,000 before deducting placement agent fees and other estimated offering expenses. The Company intends to use the net proceeds for working capital and other general corporate purposes.

  • PR Newswire4 months ago

    Cannabics Pharmaceuticals to Present Results of Clinical Trial at International Medical Cannabis Conference

    TEL AVIV, Israel and BETHESDA, Maryland, Sept. 21, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on Cancer and its side effects, today announced that Dr. Gil Bar-Sela is scheduled to present his findings at the 3rd International Medical Cannabis Conference. This Conference is held for global leaders in areas of Medical Cannabis to convene, explore and present the latest scientific and clinical research in medical cannabis, held in Tel Aviv from October 14th-16th, 2018. Dr. Bar-Sela is the Deputy Director of the Division of Oncology at Rambam Health Care Campus, Head of the Palliative and Supportive Oncology Unit, and Head of the service for Melanoma and Sarcoma patients.

  • ACCESSWIRE4 months ago

    Cannabis and Tech Stocks You Can't Afford to Miss

    HENDERSON, NV / ACCESSWIRE / September 20, 2018 / The Emerging Industries can bring investors gains bigger than one finds in almost any other marketplace. We found a few microcaps that could be the next ...

  • Eroll Grow Tech (Seedo) Merges Its Activities With GRCR Partners; Cannabics Pharmaceuticals to Own 13.6% in the Merged Company
    PR Newswire4 months ago

    Eroll Grow Tech (Seedo) Merges Its Activities With GRCR Partners; Cannabics Pharmaceuticals to Own 13.6% in the Merged Company

    TEL AVIV, Israel and BETHESDA, Maryland, Sept. 18, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that its partner, Eroll Grow Tech (Seedo), has acquired the majority of shares in GRCR partners, which is publicly traded on the OTC market under the symbol GRCR, as announced yesterday. According to the transaction agreement, Eroll Grow Tech Ltd. (Seedo) will merge its operational activities into GRCR. Cannabics Pharmaceuticals, which provided funds for the transaction, shall eventually receive 13.6% of the merged company, along with a Promissory Note of $350,000 debt owed by Seedo.

  • Cannabics Pharmaceuticals Receives Positive Results in the Development of Cannabinoid-anticancer Drugs
    PR Newswire4 months ago

    Cannabics Pharmaceuticals Receives Positive Results in the Development of Cannabinoid-anticancer Drugs

    TEL AVIV, Israel and BETHESDA, Maryland, Sept. 14, 2018 /PRNewswire/ --  Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced it has received encouraging results in its preclinical study showing one of its proprietary cannabinoid compounds causing higher rate of cancer cell death compared to traditional chemotherapy (fig.1). Cannabics is rapidly expanding its database of cancer and cannabinoids and established a library of cannabinoid compounds to explore the biological versatility and entourage effect. Recently the company has been granted a patent in Israel on its core technology of screening the effectiveness of cannabis compounds on human biopsies.

  • Cannabics Pharmaceuticals Granted Patent in Israel for Its Core Technology for Personalized Cannabinoid Based Medicine
    PR Newswire5 months ago

    Cannabics Pharmaceuticals Granted Patent in Israel for Its Core Technology for Personalized Cannabinoid Based Medicine

    TEL AVIV, Israel and BETHESDA, Maryland, Sept. 5, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, has been granted its patent for its core technology by the Israeli Patent Office. This patent encompasses the systems and methods required to produce data on the interaction between different cannabinoids and cancer cells. This technology enables screening the effects of a multitude of compounds derived from the cannabis plant on cancer cell lines and biopsies.

  • PR Newswire5 months ago

    Cannabics Pharmaceuticals Inc. Appoints Dr. Estery Giloz-Ran to Its Advisory Board

    Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, Board of Directors is proud to announce its addition of Dr Giloz-Ran, former manager of Grants Capital Investment, at INTEL Corporation, Israel - to its advisory board. "We are honored to have Dr. Giloz-Ran join our Board of Advisors, her exceptional record in international business management suits us well as our state-of-the-art laboratory comes into operation and we are being approached by potential medical partners to explore joint ventures," said Eyal Ballan, CTO.

  • Cannabics Pharmaceuticals Announces That Seedo is to End Pre-Sales and Commence Delivery of Its Automated Growing Devices
    PR Newswire5 months ago

    Cannabics Pharmaceuticals Announces That Seedo is to End Pre-Sales and Commence Delivery of Its Automated Growing Devices

    Aug. 22, 2018, TEL AVIV, Israel and BETHESDA, Maryland /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that Eroll Grow Tech Ltd ("Seedo"), developer of the world's first fully-automated grow device designed specifically for medical cannabis, is to end Seedo's pre-sale on September 12th at midnight EST, and commence scheduled delivery of its first units to customers in the coming weeks. Recently CNBX partnered with Seedo to help bring forth the company's immediate vision of supplying personalized growing units into the market, and to cooperate on enabling consistent, pesticide free, pharmaceutical-grade cannabis worldwide on a commercial scale.

  • Cannabics Pharmaceuticals Partners with Eroll Grow Tech to Create First Auto-Grow Device for Medical Cannabis
    PR Newswire5 months ago

    Cannabics Pharmaceuticals Partners with Eroll Grow Tech to Create First Auto-Grow Device for Medical Cannabis

    TEL AVIV, Israel and BETHESDA, Maryland, Aug. 14, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced a partnership agreement with Eroll Grow Tech ltd ("Seedo"), developer of the world's first fully-automated grow device designed specifically for cannabis. Through this new partnership, Cannabics and Seedo will develop the first controlled device for growing medical cannabis at home, ensuring sustainable quality and supply of natural, pesticide free product. The fully-automated grow device will be managed and controlled by an artificial intelligence algorithm and monitored by a smart phone app, using technology successfully implemented by Seedo for recreational growth.